Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS

Background: Risk models (RM) need external validation to assess their value beyond the setting in which they were developed. We validated a RM combining mpMRI and clinical parameters for the probability of harboring significant prostate cancer (sPC, Gleason Score ≥ 3+4) for biopsy-naïve men. Materi...

Full description

Saved in:
Bibliographic Details
Main Authors: Radtke, Jan Philipp (Author) , Nyarangi-Dix, Joanne (Author) , Schütz, Viktoria (Author) , Dieffenbacher, Svenja (Author) , Görtz, Magdalena (Author) , Stenzinger, Albrecht (Author) , Bonekamp, David (Author) , Schlemmer, Heinz-Peter (Author) , Hohenfellner, Markus (Author)
Format: Article (Journal)
Language:English
Published: August 26, 2019
In: PLOS ONE
Year: 2019, Volume: 14, Issue: 8
ISSN:1932-6203
DOI:10.1371/journal.pone.0221350
Online Access:Verlag, Volltext: https://doi.org/10.1371/journal.pone.0221350
Verlag: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221350
Get full text
Author Notes:Jan Philipp Radtke, Francesco Giganti, Manuel Wiesenfarth, Armando Stabile, Jose Marenco, Clement Orczyk, Veeru Kasivisvanathan, Joanne Nyaboe Nyarangi-Dix, Viktoria Schütz, Svenja Dieffenbacher, Magdalena Görtz, Albrecht Stenzinger, Wilfried Roth, Alex Freeman, Shonit Punwani, David Bonekamp, Heinz-Peter Schlemmer, Markus Hohenfellner, Mark Emberton, Caroline M. Moore

MARC

LEADER 00000caa a2200000 c 4500
001 167874798X
003 DE-627
005 20230814095223.0
007 cr uuu---uuuuu
008 191011s2019 xx |||||o 00| ||eng c
024 7 |a 10.1371/journal.pone.0221350  |2 doi 
035 |a (DE-627)167874798X 
035 |a (DE-599)KXP167874798X 
035 |a (OCoLC)1341245168 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Radtke, Jan Philipp  |d 1985-  |e VerfasserIn  |0 (DE-588)1020328290  |0 (DE-627)688118089  |0 (DE-576)360178170  |4 aut 
245 1 0 |a Prediction of significant prostate cancer in biopsy-naïve men  |b Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS  |c Jan Philipp Radtke, Francesco Giganti, Manuel Wiesenfarth, Armando Stabile, Jose Marenco, Clement Orczyk, Veeru Kasivisvanathan, Joanne Nyaboe Nyarangi-Dix, Viktoria Schütz, Svenja Dieffenbacher, Magdalena Görtz, Albrecht Stenzinger, Wilfried Roth, Alex Freeman, Shonit Punwani, David Bonekamp, Heinz-Peter Schlemmer, Markus Hohenfellner, Mark Emberton, Caroline M. Moore 
264 1 |c August 26, 2019 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 11.10.2019 
520 |a Background: Risk models (RM) need external validation to assess their value beyond the setting in which they were developed. We validated a RM combining mpMRI and clinical parameters for the probability of harboring significant prostate cancer (sPC, Gleason Score ≥ 3+4) for biopsy-naïve men. Material and methods: The original RM was based on data of 670 biopsy-naïve men from Heidelberg University Hospital who underwent mpMRI with PI-RADS scoring prior to MRI/TRUS-fusion biopsy 2012-2015. Validity was tested by a consecutive cohort of biopsy-naïve men from Heidelberg (n = 160) and externally by a cohort of 133 men from University College London Hospital (UCLH). Assessment of validity was performed at fusion-biopsy by calibration plots, receiver operating characteristics curve and decision curve analyses. The RM`s performance was compared to ERSPC-RC3, ERSPC-RC3+PI-RADSv1.0 and PI-RADSv1.0 alone. Results: SPC was detected in 76 men (48%) at Heidelberg and 38 men (29%) at UCLH. The areas under the curve (AUC) were 0.86 for the RM in both cohorts. For ERSPC-RC3+PI-RADSv1.0 the AUC was 0.84 in Heidelberg and 0.82 at UCLH, for ERSPC-RC3 0.76 at Heidelberg and 0.77 at UCLH and for PI-RADSv1.0 0.79 in Heidelberg and 0.82 at UCLH. Calibration curves suggest that prevalence of sPC needs to be adjusted to local circumstances, as the RM overestimated the risk of harboring sPC in the UCLH cohort. After prevalence-adjustment with respect to the prevalence underlying ERSPC-RC3 to ensure a generalizable comparison, not only between the Heidelberg and die UCLH subgroup, the RM`s Net benefit was superior over the ERSPC`s and the mpMRI`s for threshold probabilities above 0.1 in both cohorts. Conclusions: The RM discriminated well between men with and without sPC at initial MRI-targeted biopsy but overestimated the sPC-risk at UCLH. Taking prevalence into account, the model demonstrated benefit compared with clinical risk calculators and PI-RADSv1.0 in making the decision to biopsy men at suspicion of PC. However, prevalence differences must be taken into account when using or validating the presented risk model. 
650 4 |a Biopsy 
650 4 |a Cancer detection and diagnosis 
650 4 |a Forecasting 
650 4 |a Lesions 
650 4 |a Magnetic resonance imaging 
650 4 |a Prostate cancer 
650 4 |a Prostate gland 
650 4 |a Ultrasound imaging 
700 1 |a Nyarangi-Dix, Joanne  |d 1978-  |e VerfasserIn  |0 (DE-588)135726956  |0 (DE-627)570570158  |0 (DE-576)300611951  |4 aut 
700 1 |a Schütz, Viktoria  |e VerfasserIn  |0 (DE-588)1183860021  |0 (DE-627)1663385335  |4 aut 
700 1 |a Dieffenbacher, Svenja  |e VerfasserIn  |0 (DE-588)1164394339  |0 (DE-627)1028840071  |0 (DE-576)508505070  |4 aut 
700 1 |a Görtz, Magdalena  |d 1992-  |e VerfasserIn  |0 (DE-588)1166813657  |0 (DE-627)1030681392  |0 (DE-576)510916600  |4 aut 
700 1 |a Stenzinger, Albrecht  |e VerfasserIn  |0 (DE-588)139606106  |0 (DE-627)703395238  |0 (DE-576)312432755  |4 aut 
700 1 |a Bonekamp, David  |d 1977-  |e VerfasserIn  |0 (DE-588)128868104  |0 (DE-627)383668581  |0 (DE-576)297371797  |4 aut 
700 1 |a Schlemmer, Heinz-Peter  |d 1961-  |e VerfasserIn  |0 (DE-588)1025559967  |0 (DE-627)722927142  |0 (DE-576)17334805X  |4 aut 
700 1 |a Hohenfellner, Markus  |d 1958-  |e VerfasserIn  |0 (DE-588)133862518  |0 (DE-627)557857988  |0 (DE-576)300155263  |4 aut 
773 0 8 |i Enthalten in  |t PLOS ONE  |d San Francisco, California, US : PLOS, 2006  |g 14(2019,8) Artikel-Nummer e0221350, 15 Seiten  |h Online-Ressource  |w (DE-627)523574592  |w (DE-600)2267670-3  |w (DE-576)281331979  |x 1932-6203  |7 nnas  |a Prediction of significant prostate cancer in biopsy-naïve men Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS 
773 1 8 |g volume:14  |g year:2019  |g number:8  |g extent:15  |a Prediction of significant prostate cancer in biopsy-naïve men Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS 
856 4 0 |u https://doi.org/10.1371/journal.pone.0221350  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221350  |x Verlag 
951 |a AR 
992 |a 20191011 
993 |a Article 
994 |a 2019 
998 |g 133862518  |a Hohenfellner, Markus  |m 133862518:Hohenfellner, Markus  |d 910000  |d 910200  |e 910000PH133862518  |e 910200PH133862518  |k 0/910000/  |k 1/910000/910200/  |p 18 
998 |g 1025559967  |a Schlemmer, Heinz-Peter  |m 1025559967:Schlemmer, Heinz-Peter  |d 50000  |e 50000PS1025559967  |k 0/50000/  |p 17 
998 |g 128868104  |a Bonekamp, David  |m 128868104:Bonekamp, David  |d 50000  |e 50000PB128868104  |k 0/50000/  |p 16 
998 |g 139606106  |a Stenzinger, Albrecht  |m 139606106:Stenzinger, Albrecht  |d 910000  |d 910200  |e 910000PS139606106  |e 910200PS139606106  |k 0/910000/  |k 1/910000/910200/  |p 12 
998 |g 1166813657  |a Görtz, Magdalena  |m 1166813657:Görtz, Magdalena  |d 910000  |d 910200  |e 910000PG1166813657  |e 910200PG1166813657  |k 0/910000/  |k 1/910000/910200/  |p 11 
998 |g 1164394339  |a Dieffenbacher, Svenja  |m 1164394339:Dieffenbacher, Svenja  |d 910000  |d 910200  |e 910000PD1164394339  |e 910200PD1164394339  |k 0/910000/  |k 1/910000/910200/  |p 10 
998 |g 1183860021  |a Schütz, Viktoria  |m 1183860021:Schütz, Viktoria  |d 910000  |d 910200  |e 910000PS1183860021  |e 910200PS1183860021  |k 0/910000/  |k 1/910000/910200/  |p 9 
998 |g 135726956  |a Nyarangi-Dix, Joanne  |m 135726956:Nyarangi-Dix, Joanne  |d 910000  |d 910200  |e 910000PN135726956  |e 910200PN135726956  |k 0/910000/  |k 1/910000/910200/  |p 8 
998 |g 1020328290  |a Radtke, Jan Philipp  |m 1020328290:Radtke, Jan Philipp  |d 50000  |e 50000PR1020328290  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN167874798X  |e 3521654028 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["167874798X"],"doi":["10.1371/journal.pone.0221350"]},"recId":"167874798X","type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Jan Philipp Radtke, Francesco Giganti, Manuel Wiesenfarth, Armando Stabile, Jose Marenco, Clement Orczyk, Veeru Kasivisvanathan, Joanne Nyaboe Nyarangi-Dix, Viktoria Schütz, Svenja Dieffenbacher, Magdalena Görtz, Albrecht Stenzinger, Wilfried Roth, Alex Freeman, Shonit Punwani, David Bonekamp, Heinz-Peter Schlemmer, Markus Hohenfellner, Mark Emberton, Caroline M. Moore"]},"language":["eng"],"relHost":[{"disp":"Prediction of significant prostate cancer in biopsy-naïve men Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADSPLOS ONE","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"text":"14(2019,8) Artikel-Nummer e0221350, 15 Seiten","issue":"8","year":"2019","volume":"14","extent":"15"},"corporate":[{"display":"Public Library of Science","role":"isb"}],"title":[{"title":"PLOS ONE","title_sort":"PLOS ONE"}],"pubHistory":["1.2006 -"],"id":{"zdb":["2267670-3"],"eki":["523574592"],"issn":["1932-6203"]},"recId":"523574592","name":{"displayForm":["Public Library of Science"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"PLOS ; PLoS","dateIssuedDisp":"2006-","dateIssuedKey":"2006","publisherPlace":"San Francisco, California, US ; Lawrence, Kan."}],"note":["Schreibweise des Titels bis 2012: PLoS ONE","Gesehen am 20.03.19"]}],"title":[{"subtitle":"Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS","title_sort":"Prediction of significant prostate cancer in biopsy-naïve men","title":"Prediction of significant prostate cancer in biopsy-naïve men"}],"person":[{"family":"Radtke","given":"Jan Philipp","role":"aut","display":"Radtke, Jan Philipp"},{"role":"aut","display":"Nyarangi-Dix, Joanne","given":"Joanne","family":"Nyarangi-Dix"},{"display":"Schütz, Viktoria","role":"aut","family":"Schütz","given":"Viktoria"},{"family":"Dieffenbacher","given":"Svenja","display":"Dieffenbacher, Svenja","role":"aut"},{"role":"aut","display":"Görtz, Magdalena","family":"Görtz","given":"Magdalena"},{"given":"Albrecht","family":"Stenzinger","role":"aut","display":"Stenzinger, Albrecht"},{"given":"David","family":"Bonekamp","role":"aut","display":"Bonekamp, David"},{"given":"Heinz-Peter","family":"Schlemmer","display":"Schlemmer, Heinz-Peter","role":"aut"},{"display":"Hohenfellner, Markus","role":"aut","family":"Hohenfellner","given":"Markus"}],"physDesc":[{"extent":"15 S."}],"note":["Gesehen am 11.10.2019"],"origin":[{"dateIssuedDisp":"August 26, 2019","dateIssuedKey":"2019"}]} 
SRT |a RADTKEJANPPREDICTION2620